Fritextsökning
Innehållstyper
-
Roche sänker budet på Genentech
I juli ifjol var budet 89 dollar per aktie. Då sa Genentechs styrelse nej tack. Nu meddelar läkemedelsjätten att man sänker budet och vänder sig direkt till småägarna.
-
Sophion etablerar sig i Japan
Öppnar nytt sälj och supportkontor som ska ledas av en ledande japansk elektrofysiolog.
-
Danska elitforskare belönas
Totalt 45 forskare får dela på 12 miljoner vid årets utdelning av det danska Eliteforskpriset. Ett av årets stora EliteForskpris går till en ung hjärnforskare s...
-
Chr. Hansen köper underlivshälsa
Nio studer har bevisat att Urex kan minska risken för underlivsinfektioner hos kvinnor. Nu flyttas det kanadensiska bolagets verksamhet till Köpenhamn.
-
Lunds nya rektor har tillträtt
Nu är han på plats. Vinnovas förre generaldirektör tar över rodret vid Lunds universitet.
-
Carl Borrebaeck blir vicerektor i Lund
Universitetsledningen i Lund förstärks med tre nya vicerektorer. Dessutom blir det en extra satsning på ledarskap, lärarskap och innovationer.
-
Grönt ljus för Getinges bolagsköp
Medicinteknikföretaget Getinge har fått godkännande från den amerikanska konkurrensmyndigheten Federal Trade Commission, FTC för köpet av bolaget Datascope Corp...
-
Han blir Alphahelix nya VD
Bolagets tidigare teknikchef tar ett steg upp.
-
Elekta säljer cancerteknik till Ryssland
Två ledande cancerkliniker i Moskva och Sibirien får Rysslands mest avancerade system för strålterapi.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and on...
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at app...
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study...
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.